Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies?

This publication has 50 references indexed in Scilit:

• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
  The Lancet, 2005
• Rosiglitazone Protects Against Cyclosporine‐Induced Pancreatic and Renal Injury in Rats
  American Journal of Transplantation, 2005
• Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS)
  American Journal of Kidney Diseases, 2005
• The effect of high glucose and PPAR-γ agonists on PPAR-γ expression and function in HK-2 cells
  American Journal of Physiology-Renal Physiology, 2004
• Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses
  Kidney International, 2004
• Role of Sterol Regulatory Element-binding Protein 1 in Regulation of Renal Lipid Metabolism and Glomerulosclerosis in Diabetes Mellitus
  Journal of Biological Chemistry, 2002
• Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats
  Kidney International, 2001
• Peroxisome proliferator-activated receptor γ1 (PPARγ1) expresses in rat mesangial cells and PPARγ agonists modulate its differentiation
  Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2000
• Effects of pioglitazone on calcium channels in vascular smooth muscle.
  Hypertension, 1994
• Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats.
  Hypertension, 1993